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Process Analytical Technology (PAT) For Continuous Bioprocessing
 Edita Botonjic-Sehic PhD, Sr. Principal R&D Scientist, Analytics and Controls; Steven Harris, Scientist II, Analytics and Controls, Pall Corporation, 20 Walkup Drive, Westborough MA 01581
What to expect in the next 25 years?
“Right now, manufacturing experts from the 1950s would easily recognize the pharmaceutical manufacturing 
processes of today. It is predicted that manufacturing will change in the next 25 years as current manufacturing 
practices are abandoned in favor of cleaner, flexible, more efficient continuous manufacturing.”  Janet Woodckock, 
Director CDER, FDA (AAPS meeting, 2011)
Pall Life Sciences is assessing the needs process analytical technology (PAT) as an overall capability upgrade to 
be used in conjunction with our existing and planned continuous bioprocessing toolbox to enable on-line and at-
line real time continuous monitoring and automation of the continuous products.
PAT paves the way of continuous maufacturing with the adoption of innovative technologies to perform timely 
measurements on critical quality attributes (CQAs) of raw and in-process materials, allowing better process 
understanding and control.
What is Continuous Bioprocessing?
Figure 1a
Current: Batch BioProcess* (individual unit operations)   
Figure 1b
Future: Continuous BioProcess* (one piece flow)
To implement a strategy in a continuous process, it is crucial to understand and minimize:
  incoming material variation, 
  critical quality attributes (CQA) and critical process parameter (CPP) variations,
  perform timely in-process measurements, 
  define representative sampling, 
  develop chemometric models and set appropriate acceptance criteria, and 
  characterize the propagation of changes and disturbances through the system. 
In contrast to batch processing, in which local control of each piece of equipment is in many occasions considered 
sufficient, in continuous manufacturing not only is local control mandatory, but also the entire process flow must 
be coordinated and equipped with second-level control systems that supervise and align the work of individual 
unit operations.
  The selection of appropriate PAT tools is a crucial step toward setting efficient monitoring and control 
strategies in continuous processes. 
   easy-to-use instrumentation, 
   measuring frequencies, 
   ability to monitor multiple process parameters,
   directly measure CQAs, 
   capturing the real-time process state, and
   eliminate traditional off-line techniques and increase efficiency.
An example of data obtained using off-line analytics; however this could be trended in real-time via PAT tools in the future.
Key critical quality attributes that could be measured on-line and/or at line are:
 Bioburden
 Product concentration
 Host cell protein (HCP)
 Aggregates
 Glycosylation profiles
 Metabolites, etc…
Figure 2 
Percent aggregation by size-exclusion HPLC* 
Figure 3
Protein concentration (mg/mL)*
Figure 4
Host Cell Protein per mg of mAb*   
In order to ensure product quality, mAb concentration monitoring is one of the CQA’s
Figure 5
The ideal continuous controls platform combines automation, analytics and process control strategy; 
empowering users to execute advanced processes with excellence in quality, yield, and ROI
 True continuous tools (sensors, PAT, new data processing approaches)
 Data Management, Data Analysis, Data Insight and Automation
 Fill in the gaps using established platforms to meet new continuous requirements
Value of PAT implementation
  Ensure consistent product quality and increase robust overall manufacturing performance reducing heterogeneity
  Enable end-to-end continuous process by implementing lean, flexible and portable biomanufacturing
 Advanced computational tools enhance continuous monoclonal antibody production
  Integration of process analytical tools for monoclonal antibody toxicology measurement can be achieved
  Process time and cost savings can be achieved through automation and continuous integration in existing facilities
OUTLOOK
Efciency, Simplicity, Flexibility, Quality, Cost, Smaller Facility Footprint 
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*Note Abreviations: Pro-A (Protein A), VI (Virus Inactivation), D/S (Depth and Sterile Filtration), MQ (Anion Exchange), CMM (Mixed Mode Cation 
Exchange), SSV (Pegasus Prime VF), ILDF (In-line difiltration), ILC (In-line Concentration)
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21 hour continuous production of mAb  
INTRODUCTION
USING PAT TO SET MONITORING AND CONTROL STRATEGIES
IMPORTANT CQAs FOR CONTINUOUS OPERATIONS
IMPORTANT CQAs FOR CONTINUOUS OPERATIONS
CHEMOMETRIC MODELS FOR CONTINUOUS BIOPROCESSING:  
CONCENTRATION MONITORING THROUGHOUT THE CONTINUOUS PROCESS
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